A venture capital firm with a major presence in Europe invests in life science companies through various funds. The firm targets seed, venture, and growth-stage investments in European companies but also considers North American and Asian opportunities. Initial investment size ranges from €500K – 10M, preferentially in the form of straight equity. The firm is capable of leading or co-investing in financing rounds; however, for U.S. deals, the firm prefers a local investor to lead unless it is a later-stage round (i.e., B, C, etc.) and the prior round was led by a U.S. investor. The firm has greater flexibility for European-based companies and typically leads these rounds. The firm is currently in investing mode, actively seeking opportunities, with the average investment ranging from €3–5M.
The firm takes a true venture approach to investing and prioritizes breakthrough technologies with a strong IP position. Microbiome therapeutics and platforms are the primary interest, with willingness to invest as early as pre-clinical in this subsector. For other therapeutics, preferred phases of development are typically limited to pre-clinical investments into companies with a platform technology rather than those reliant on a single therapeutic asset. Medical technology and connected health companies are also evaluated, regardless of stage.
The firm prefers to work with mature, experienced management teams but is open to all entrepreneurs. The firm will invest in pre-revenue as well as revenue-generating companies, with maximum revenues of €50M.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment